TECHNOLOGY DEVELOPMENT, MAPPING, AND DNA SEQUENCING IN SUPPORT OF THEHUMAN GENOME PROGRAM NIH GUIDE, Volume 21, Number 9, March 6, 1992 PA NUMBER: PA-92-50 P.T. 34 Keywords: Human Genome Nucleic Acid Sequencing Molecular Genetics Information Science/Systems National Center for Human Genome Research PURPOSE The National Center for Human Genome Research (NCHGR) invites applications to support research that will significantly advance progress toward achieving the scientific goals of the Human Genome Program. A summary of these goals are: completion of a high density genetic linkage map of the human genome; construction of a high- resolution physical map comprised of large contigs (overlapping pieces of cloned DNA); development of a "sequence-tagged site" (STS) map; development of technology to reduce the expense of DNA sequencing significantly below current cost; development of computer tools to manage and provide access to mapping and sequencing data; examination of the legal, ethical, and social implications of the Human Genome Program; and research training. ELIGIBILITY REQUIREMENTS Domestic universities, medical colleges, hospitals, and other public, private, and for-profit research institutions, including state and local government units, are eligible. Foreign organizations are also eligible to apply only for the research project grants (R01). Applications from minority individuals and women are encouraged. MECHANISM OF SUPPORT Support for this program will be through research project grants (R01), pilot projects and feasibility studies (R21), program project grants (P01), and FIRST Awards (R29). As part of this effort, the NCHGR encourages the support of minority students and faculty interested in the Human Genome Program through the traditional NIH funding mechanisms and through minority supplements to ongoing research grants (see announcement in the NIH Guide for Grants and Contracts, Vol. 21, No. 3, Part 1 of 2, January 24, 1992). Applications to support large, complex research programs through the center grant mechanism will not be considered under this Program Announcement. Applications for P30 and P50 center grants may respond to the Program Announcement in the NIH Guide for Grants and Contracts, Vol. 18, No. 36, October 13, 1989. RESEARCH OBJECTIVES Background The NIH Human Genome Program is envisioned as a 15-year project that has very specific goals. The NCHGR was established in October 1989 for the purpose of planning and supporting the Human Genome Program at NIH and coordinating the NIH component of this program with those of other Federal agencies and international groups. The goals for the first five years of the U.S. Human Genome Program were established by a joint advisory committee of the NIH and the Department of Energy and are set forth in the document, "Understanding Our Genetic Inheritance - The U.S. Human Genome Project: The First Five Years - FY 1991-1995." (This document is available from the Human Genome Management Information System, Oak Ridge National Laboratory, Oak Ridge, TN 37831-6050; telephone, 615-576-6669). These goals are: o construction of high-resolution genetic linkage maps based on DNA markers with a goal of achieving an average spacing of 2 centimorgans and gaps no greater than 5 centimorgans between markers, each of which is identified by an STS (Olson et al., Science 245:1434, 1989); o construction of high resolution physical maps of chromosomes in which contigs of at least 2 million base pairs are unambiguously ordered and identified by STS spaced about 100,000 base pairs apart; o development of new methods for DNA sequencing that significantly reduce the cost and increase the rate of sequencing; o development of computer tools, information systems, and strategies for collecting, storing, retrieving, analyzing, interpreting, and distributing large amounts of mapping and sequencing data; o examination of legal, ethical, and social implications of the Human Genome Program (see Program Announcement in NIH Guide for Grants and Contracts, Vol. 19, No. 4, January 26, 1990); and o research training (see Program Announcement in NIH Guide for Grants and Contracts, Vol. 18, No. 25, July 21, 1989). The objective of this Program Announcement is to stimulate research that will assist the NCHGR in accomplishing both the short- and long-term scientific goals of the Human Genome Program in the most expeditious and cost-saving manner. This Program Announcement supersedes the one that was published in the NIH Guide for Grants and Contracts, Vol. 19, No. 28, 1990. In planning research projects, applicants should be cognizant of the following: Technology Development. Although a number of the techniques currently in use for mapping have proven useful in initial successes in building megabase-size contigs and studying specific genomic regions, it is anticipated that new technologies, strategies and approaches are still needed to reach the final mapping goal of the Human Genome Program most expeditiously and in a cost-effective manner. Similarly, the technology currently available for sequencing and data handling is not capable of supporting the goals of the Human Genome Program in these areas. Therefore, in the first five years of the Human Genome Program, emphasis will be placed on technology development in all phases of mapping, sequencing and informatics. For applications with the primary objective of map construction, those that improve or propose new technology as a significant component will be most competitive. This will also be the case in mapping, sequencing, and informatics applications. Research projects that focus on technology development in the context of a particular disease gene are appropriate if such projects have one or more of the overall objectives of the Human Genome Program as a major research goal. Collaborative Research. In order to achieve the objectives of the Human Genome Program, collaborations between biologists from various disciplines, including human genetics, as well as between biologists and non-biologists, such as chemists, physicists, information scientists, and engineers, are essential. The NCHGR strongly encourages multidisciplinary collaboration to facilitate progress, especially in technically sophisticated areas. Duplication/Overlap. A certain amount of duplication in research is inevitable and, in fact, is useful for verifying or validating experimental results. However, given the limited resources and the need to accomplish the goals of the Human Genome Program within the proposed 15-year period, duplication of research, irrespective of funding source, while encouraged, should be kept to a minimum. To assist applicants with respect to what research is supported through the NCHGR, a list of the Human Genome Program grant portfolio is available to potential applicants. Sharing of Materials and Data. The sharing of materials and data in a timely manner is essential for progress towards the goals of the Human Genome Program, to avoid unnecessary duplication, and to facilitate research in other areas of biomedical research. The Public Health Service (PHS) policy requires the sharing of resources at the time of publication. For some projects that will be supported by the NCHGR, this policy is not sufficient because certain kinds of data may not be published in their entirety, while some information or resources need to be shared more rapidly than at the time of publication. Because the type of research will dictate the conditions under which data and materials should be shared, applicants should, in their applications, discuss their plans for sharing data and materials and depositing data and materials to appropriate repositories. It is expected that, whenever appropriate, resources such as cell lines, probes, and sequence data, will be deposited expeditiously in public repositories. Investigators may request funds to defray the costs of sharing materials and submitting data to repositories in their applications. However, such requests must be adequately justified. For applications assigned to the NCHGR, the plans for sharing will be reviewed for adequacy by NIH staff and the National Advisory Council on Human Genome Research prior to award of a grant. Animal Models. Research involving model systems will contribute greatly to the Human Genome Program. The five- year plan includes, as one of its goals, the support of mapping and sequencing of the DNA of five specific organisms: E. coli, S. cerevisiae, D. melanogaster, C. elegans, and the laboratory mouse. The Human Genome Program is, therefore, interested in promoting research using these organisms. However, research projects involving other model organisms may also contribute significantly to the goals of the Human Genome Program. Thus, applicants may propose to study model systems other than those listed. In those cases, the choice of organism must be justified in terms of the overall objectives of the Program. Whereas the "Research Objectives" described below do not specify research to be conducted on model organisms, such research is encouraged. Pilot Projects or Feasibility Studies. The NCHGR is interested in supporting scientifically sound projects that are novel, creative, or high risk/high payoff. Applicants who seek funding to support such research and need limited funding to conduct preliminary studies should submit applications in response to the Program Announcement "Pilot Projects or Feasibility Studies for Genomic Analysis," (see NIH Guide for Grants and Contracts, Vol. 19, No. 28, July 27, 1990). Specific Research Objectives In order to achieve the goals of the Human Genome Program, applications that propose to develop new approaches and strategies to mapping and sequencing problems, as well as those that propose creative, novel, high-risk/high-payoff strategies, are highly encouraged. All researchers applying for support should (l) address how the proposed research will help accomplish the five-year goals; (2) discuss new approaches and/or technology as part of the mapping or sequencing strategy; (3) approach the problem in a comprehensive manner, irrespective of the size of the project (e.g., in constructing a physical map of a particular chromosome, emphasis should be placed on constructing fully connected contigs, i.e., overlapping units of cloned DNA, rather than just mapping available probes); (4) demonstrate that there are adequate plans for: (a) data management, (b) interacting and collaborating with the rest of the scientific community working on similar or related objectives, and (c) making data and resources publicly available in a timely manner; and (5) in the case of specific mapping and technology development applications, address how the proposed research project will relate to or augment existing research efforts. Genetic Linkage Maps High-density genetic linkage maps are important for attainment of the goals of the Human Genome Program as they will facilitate (1) the identification of gene locations and (2) the construction of a complete physical map by allowing contigs (overlapping clones of DNA) to be ordered with respect to one another. The Human Genome Program has set as one of its goals during the first five years the creation of a 2 to 5 centimorgan human genetic linkage map. A map of this resolution would require 1500 to 2000 informative markers evenly spaced along the genome; in addition each DNA marker would be defined by a unique STS. An STS is defined as a DNA marker that is unique in the genome and can be detected by the polymerase chain reaction. The STS concept has been promoted as a device that will allow mapping data from different laboratories and from different types of maps to be merged or assimilated. To facilitate completion of a high-density genetic map, applications are encouraged in the following areas: o Development of methods to rapidly and efficiently isolate, identify, and map highly informative markers. o Expansion of the maps of individual chromosomes with the goal of achieving a high-resolution map comprised of DNA markers with an average spacing of 2 centimorgans and gaps no greater than 5 centimorgans, and with each marker identified by an STS. Applications are particularly encouraged for projects addressing those chromosomes or regions of chromosomes where there are presently few markers or those approaching the completion of the genetic map using a genomic, rather than a chromosome-by-chromosome, strategy. o Improvement of methods for linkage analysis and ordering of markers. o Closure methods targeted to finding and mapping markers within gaps in existing maps. o Technology development to accelerate completion of a 2-5 centimorgan map of the human genome. Physical Maps A physical map is a very useful resource because it is the basis for characterizing and isolating individual genes or other DNA regions of interest and is a prerequisite for large-scale DNA sequencing. There are several types of physical maps including cytogenetic maps, long-range restriction maps and contig maps. To facilitate the construction of a complete physical map, at least two aspects of mapping need to be improved: (1) the length of a DNA segment that can be routinely covered by a single contig or spanned by a set of closely spaced ordered markers must be increased and (2) methods for closure or filling in the gaps between contigs also need to be developed or improved. To facilitate completion of a fully connected physical map, research projects in the following areas are encouraged: o Development of methods for isolating large amounts of purified human chromosomes, chromosome segments, and restriction fragments for mapping and sequencing. o Development of cloning techniques that improve upon current approaches to constructing complete physical maps. The development of reproducible methods that: (1) ensure that cloned inserts are stable and are at least one megabase in size, (2) avoid artifacts, such as dimeric clones, and (3) ensure that cloned fragments derived from a single chromosomal location are particularly encouraged. o Construction of overlapping sets of cloned DNA, or closely spaced, unambiguously ordered DNA markers, with continuity over lengths of at least 2 million base pairs. o Assembly of STS maps of individual human chromosomes with the goal of having the STS markers spaced at approximately 100,000 base pair intervals. o Development of methods or strategies to solve the problem of closure. o Technology development to accelerate the completion of the physical map of the human genome. Sequencing The ultimate goal of the Human Genome Program is to determine the complete sequence of the human genome. To date, the largest genome that has been sequenced is a viral genome that is 240,000 base pairs in length. The human genome is 3 billion base pairs in length, four orders of magnitude larger. The current cost of DNA sequencing, in laboratories that do it routinely, is estimated to be between $2-5 per base pair of finished sequence. If the entire human genome is to be sequenced, the cost of sequencing must be significantly reduced. Applications responding to this Program Announcement must address innovative approaches, including automation, that will increase the speed of sequencing megabases of DNA and significantly decrease the cost of DNA sequencing to $0.50 or less per finished base pair within five years. Research projects are encouraged in the following areas: o Improvement of current technologies in order to reduce costs significantly below current costs; o Development of new methods, technologies, and strategies for large-scale sequencing including preparing and sequencing the DNA and assembling the data. Only applications that aim to develop new or significantly improved current sequence technology should be submitted in response to this Program Announcement. Applications for routine sequencing will not be supported by the NCHGR. Applications to support feasibility studies for large-scale DNA sequencing using advanced state-of-the-art technology may be submitted only in response to a Request for Applications that is issued periodically in the NIH Guide for Grants and Contracts. Informatics The Human Genome Program will generate mapping and sequencing data from many laboratories, both national and international. While some computer tools and information systems for handling this type of data exist, none have been tested on a large scale to determine their capabilities to manage the voluminous amount and complexity of the data that will be generated. There is a need to develop appropriate computer tools and information systems for the collection, storage, retrieval, and distribution of mapping and sequencing data. In addition to the development of databases, it will be necessary to develop new methods and tools for the analysis and interpretation of genome maps and DNA sequences. Research projects are encouraged in the following general areas: o Development of effective software and database designs to support laboratory-based, large-scale mapping and DNA sequencing projects. Such projects should be undertaken in the context of actual mapping and sequencing efforts. o Creation of database and/or software tools that provide easy access to up-to-date physical and genetic mapping and DNA sequencing information and allow linkage of these specific data sets. o Development of analytical tools that can be used in the assembly and analysis of genomic data. o Technology development to accelerate the collection, storage, retrieval, analysis, and distribution of mapping and sequencing data. APPLICATIONS PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 9/91). Applications will be accepted on the receipt dates for research grant applications (February 1, June 1, October 1). Application kits are available at most institutional business and grant/contract offices and may be obtained from the Division of Research Grants, National Institutes of Health, Westwood Building, Room 240, Bethesda, MD 20892, telephone 301/496-7441. The title and number of this announcement must be typed in Item 2 on the face page of the application. The completed original application and five legible copies must be delivered to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** STUDY POPULATIONS SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical research grants and cooperative agreements will be required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder or condition under study; special emphasis should be placed on the need for inclusion of minorities and women in studies of diseases, disorders and conditions which disproportionately affect them. This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed population-based studies, a clear compelling rationale should be provided. The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues should be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information should be included in the form PHS 398 in Section 2, A-D of the Research Plan AND summarized in Section 2, E, Human Subjects. Applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., Native Americans (including American Indians or Alaskan Natives), Asian/Pacific Islanders, Blacks, Hispanics). The rationale for studies on single minority population groups should be provided. For the purpose of this policy, clinical research includes human biomedical and behavioral studies of etiology, epidemiology, prevention (and preventive strategies), diagnosis, or treatment of diseases, disorders or conditions, including but not limited to clinical trials. The usual NIH policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants. For foreign awards, the policy on inclusion of women applies fully; since the definition of minority differs in other countries, the applicant must discuss the relevance of research involving foreign population groups to the United States' populations, including minorities. If the required information is not contained within the application, the application will be returned. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and will be reflected in assigning the priority score to the application. All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not award grants or cooperative agreements that do not comply with these policies. REVIEW CONSIDERATIONS Applications in response to this announcement will be reviewed in accordance with the usual NIH peer review procedures. With the exception of program project (P01) applications, applications will be reviewed for scientific and technical merit by an appropriate study section in the Division of Research Grants. Program project applications will be evaluated by an appropriate review committee managed by an Institute or Center. Following the initial scientific review, applications will receive a second-level review by the National Advisory Council for Human Genome Research or another Council or Board. Review Criteria Review criteria that will be used to assess the scientific merit are: o Significance and originality of the research and methodological approaches; o Feasibility of the research and adequacy of the experimental design; o Training, experience, research competence, and commitment of the investigator(s); o Adequacy of the facilities and resources; o Appropriateness of the requested budget for the work proposed. AWARD CRITERIA Applications will compete for available funds with all other approved applications. The following will be considered in making funding decisions: o Quality of the proposed project as determined by peer review; o Balance among research areas; o Availability of funds. For those applications assigned to the NCHGR, the following additional criteria will be used in making award decisions: o Potential for developing technology or strategies for accelerating progress in mapping and sequencing the genomes of human and select model organisms; o Value of the research for achieving the goals of the National Center for Human Genome Research; o Adequacy of any plans proposed for managing data and sharing data and resources in a timely manner; In addition, priority will be given to applications from U.S. institutions. INQUIRIES The program administrators and grants management officer welcome the opportunity to discuss the program interests of the NCHGR and PHS grants policy, respectively, with prospective applicants and current grantees and encourages telephone, electronic and written inquiries. For additional information, contact: Genetic and Physical Mapping Grant Applications Bettie J. Graham, Ph.D. Chief, Research Grants Branch National Center for Human Genome Research Building 38A, Room 613 Bethesda, MD 20892 Telephone: (301) 496-7531 E-mail: B2G@CU.NIH.GOV Sequencing and Technology Development Grant Applications Robert L. Strausberg, Ph.D. Program Director, Technology Development Program National Center for Human Genome Research Building 38A, Room 610 Bethesda, MD 20892 Telephone: (301) 496-7531 E-mail: CXR@CU.NIH.GOV Informatics Applications David Benton, Ph.D. Assistant to the Director for Scientific Data Management National Center for Human Genome Research Building 38A, Room 610 Bethesda, MD 20892 Telephone: (301) 496-7531 E-mail: BENTON@BIO.NLM.NIH.GOV PHS Grants Policy Ms. Alice Thomas Chief, Grants and Contracts Management Branch National Center for Human Genome Research Building 38A, Room 613 Bethesda, MD 20892 Telephone: (301) 402-0733 AUTHORITY AND REGULATION This program is described in the Catalog of Federal Domestic Assistance No. 93.172. Awards will be made under the authority of the Public Health Service Act, Section 301 (Public Law 78-410, as amended 42 U.S.C. 241) and administered under PHS grants policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or to Health Systems Agency review. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |